What Prenetics Global (PRE) Said on Its Q3 Earnings Call

Prenetics Global logo with Consumer Staples background
Image from MarketBeat Media, LLC.

Key Points

  • Revenue surged: Third-quarter revenue was $64.1 million, up 37.9% sequentially, with IM8 contributing $62.9 million. Prenetics reaffirmed its 2026 revenue forecast of $220 million to $230 million.
  • Higher marketing investment is widening expected losses: The company raised its second-half adjusted EBITDA loss forecast to $30 million–$35 million from $8 million–$12 million, citing returns from customer acquisition spending. IM8 added nearly 138,000 customers in the quarter, while average acquisition cost fell to $285.
  • Prenetics reiterated its growth ambitions: It maintained its target of at least $400 million in IM8 revenue for 2027 and plans to launch Hydration and Care Bears products that year. General Catalyst financing helped support positive adjusted free cash flow in Q3, despite negative operating cash flow.
  • MarketBeat previews top five stocks to own in December.

Prenetics Global NASDAQ: PRE reported third-quarter revenue of $64.1 million as sales of its IM8 supplement brand climbed, but widened its expected second-half adjusted EBITDA loss as it plans to spend more on customer acquisition.

The company now expects an adjusted EBITDA loss of $30 million to $35 million for the second half of 2026, compared with its previous forecast for a loss of $8 million to $12 million. Chief Executive Officer Danny Yeung said the increased spending reflects the returns Prenetics has seen from customers acquired through its marketing efforts.

“We will keep investing at this pace for as long as we see these returns hold up,” Yeung said. He added that the company would slow spending if customer acquisition costs or the gross profit generated by customer groups deteriorated.

Revenue Growth and Wider Net Loss

Third-quarter revenue rose 37.9% from the second quarter and was approximately 3.3 times its level in the year-earlier period, said Brian Rosin, IM8’s chief financial officer and Prenetics’ CFO designate. IM8 accounted for $62.9 million of revenue, up 39.8% sequentially.

The company posted an adjusted EBITDA loss of $12.7 million, compared with a negative adjusted EBITDA margin of 20%, an improvement from negative 39% in the prior quarter. Its net loss widened to $25.4 million from $9 million in the second quarter. Rosin said the latest loss included a $7.2 million noncash fair-value loss on warrant liabilities, while the prior quarter benefited from fair-value and disposal gains.

Gross margin was 64%, reflecting a $1.3 million inventory charge related to older product formulations. Rosin said the company expects gross margin of 65% in the fourth quarter and beyond.

Prenetics reaffirmed its 2026 revenue forecast of $220 million to $230 million, including $215 million to $222 million from IM8. That outlook implies fourth-quarter group revenue of approximately $73 million to $83 million and an adjusted EBITDA loss of roughly $17 million to $22 million, Rosin said.

Customer Acquisition and Financing

IM8 acquired 137,892 new customers in the third quarter, up approximately 16% from the prior quarter. Marketing spending for the brand rose about 10% to $39.3 million, while its average customer acquisition cost fell to $285 from $301, Rosin said.

Yeung said customer acquisition costs are likely to fluctuate around $300, plus or minus 10% to 15%, depending in part on seasonality. The company ended September with roughly 160,000 active subscriptions, and repeat orders accounted for about 59% of customer billings during the quarter.

Yeung said the customers acquired in IM8’s first full quarter of business, in early 2025, had returned $4.10 in gross profit for every dollar spent acquiring them. A group acquired in the following two quarters had returned about $2.70 per acquisition dollar, he said. Those early customers cost roughly $104 each to acquire, compared with the current average of $285.

Prenetics reported $4.1 million in positive adjusted free cash flow for the third quarter, a non-IFRS measure that included $31.6 million in net funding from General Catalyst. Operating cash flow was negative $27.5 million.

Under a growth financing commitment of up to $1 billion, General Catalyst finances 70% of eligible customer acquisition spending and receives a portion of the associated cohorts’ gross profit until its principal and a defined premium are repaid. Rosin said the company expects adjusted free cash flow to remain positive in the fourth quarter because of that financing, despite negative operating cash flow.

Cash and current financial assets totaled $111 million at the end of September, up from $109.4 million at the end of June. The balance sheet also included $34.7 million of borrowings under the General Catalyst agreement.

New Products and 2027 Outlook

Prenetics reiterated its forecast for IM8 revenue of at least $400 million in 2027. The forecast is based on its current product catalog and excludes planned Hydration and Care Bears products, as well as potential retail and China sales, Rosin said.

IM8 Hydration is planned for the first quarter of 2027, after the company moved its launch from the fourth quarter of 2026. Care Bears by IM8, beginning with gummy multivitamins for children and adults, is targeted for the second quarter of 2027 under a 10-year exclusive worldwide partnership with Authentic Brands Group.

Yeung said Prenetics expects to enter retail by the end of 2027 and is speaking with major retailers, although it has not signed retail agreements. The company also intends to launch in China by the end of 2027, subject to finding appropriate partners and meeting local regulatory requirements.

Rosin declined to give a specific timeline for positive operating cash flow or adjusted EBITDA, saying it would depend in part on how much the company continues to spend while maintaining its desired returns. He said that as the existing customer base grows, repeat revenue should increase, but continued investment could push profitability further out.

About Prenetics Global (NASDAQ:PRE)

Prenetics Global Limited is a health sciences company focused on consumer wellness and health-related products. Its portfolio includes IM8, a consumer wellness brand offering nutritional supplements, and CircleDNA, a genetic testing service that provides reports on health, wellness and ancestry. The company has also operated clinical genomic testing services and provided COVID-19 testing during the pandemic. Its business has since shifted toward consumer health and wellness. Prenetics was founded in 2014 and is led by co-founder and Chief Executive Officer Danny Yeung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Prenetics Global Right Now?

Before you consider Prenetics Global, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.

While Prenetics Global currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines